Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers

Compass Therapeutics, Inc. reported additional interim results from a Phase II study of CTX-009, a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch and VEGF-A signaling pathways, in combination with paclitaxel in patients with biliary tract cancers.